Evotec (EVO) Stock Price, News & Analysis

Company Overview

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Key Stats

• Today's Range: $4.21 to $4.30
• 50-Day Range: $2.97 to $4.46
• 52-Week Range: $2.84 to $5.68
• Volume: 41,468 shs
• Average Volume: 131,388 shs
• Market Capitalization: $1.53 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.93
• Consensus Rating: Hold

Evotec Stock Analysis - MarketRank™

Evotec scored higher than 37% of companies evaluated by MarketBeat, and ranked 785th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

Evotec has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Evotec has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Evotec are expected to grow in the coming year, from ($0.41) to ($0.18) per share.

Price to Book Value per Share Ratio

Evotec has a P/B Ratio of 1.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.20% of the float of Evotec has been sold short.

Short Interest Ratio / Days to Cover

Evotec has a short interest ratio ("days to cover") of 7.9.

Change versus previous month

Short interest in Evotec has recently decreased by 18.05%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Evotec does not currently pay a dividend.

Dividend Growth

Evotec does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.20% of the float of Evotec has been sold short.

Short Interest Ratio / Days to Cover

Evotec has a short interest ratio ("days to cover") of 7.9.

Change versus previous month

Short interest in Evotec has recently decreased by 18.05%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: 0.12

News Sentiment

Evotec has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 18 news articles for Evotec this week, compared to 3 articles on an average week.

Search Interest

Only 2 people have searched for EVO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Evotec insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.00% of the stock of Evotec is held by insiders.

Percentage Held by Institutions

Only 5.81% of the stock of Evotec is held by institutions.

EVO Stock Analysis - Frequently Asked Questions

How have EVO shares performed this year?

Evotec's stock was trading at $4.16 at the beginning of 2025. Since then, EVO shares have increased by 3.4% and is now trading at $4.30.
View the best growth stocks for 2025 here.

When did Evotec IPO?

Evotec (EVO) raised $435 million in an IPO on Thursday, November 4th 2021. The company issued 20,000,000 shares at a price of $21.75 per share.

How do I buy shares of Evotec?

Shares of EVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Evotec own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Evotec investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AUO (AUOTY), DiamondRock Hospitality (DRH), American Water Works (AWK) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Today: 4/28/2025
• Next Earnings (Estimated): 5/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EVO
• CIK: 1412558
• Web: www.evotec.com
• Phone: 49-40-560-81-0
• Fax: 49-40-5608-1222
• Employees: 4,200
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.93
• High Stock Price Target: $8.00
• Low Stock Price Target: $3.80
• Potential Upside/Downside: +38.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.43
• Current Ratio: 2.09
• Quick Ratio: 1.99

Sales & Book Value

• Annual Sales: $796.97 million
• Price / Sales: 1.92
• Cash Flow: $0.03 per share
• Price / Cash Flow: 161.08
• Book Value: $3.42 per share
• Price / Book: 1.26

Miscellaneous

• Outstanding Shares: 355,107,000
• Free Float: 350,827,000
• Market Cap: $1.53 billion
• Optionable: Not Optionable
• Beta: 1.69